Open Access Open Access  Restricted Access Subscription or Fee Access

ABCB5 and β catenin activity for colon cancer: A review

Tanvee Pardeshi, Nilamoni Kalita, Sameer Chaudhary, Sakshi Rawat


Colorectal malignancy (CRC) is the second most regularly analyzed disease among females and third among guys around the world. It likewise contributes fundamentally to growth related passing, regardless of the ceaseless advance in symptomatic and helpful techniques. Biomarkers as of now assume an imperative part in the recognition and treatment of patients with colorectal disease. This review gives an avant-garde synopsis on markers such as ABCB5 and β-catenin associated with colon cancer. Diverse ABC transporters were observed to be up-managed in colon disease, which can encourage the efflux of anticancer medications out of growth cells and lessening their helpful impacts. Examination of human colon and colorectal tumor examples uncovered ABCB5 to be communicated just on uncommon cells inside sound intestinal tissue, while clinical colorectal malignancies displayed considerably expanded levels of ABCB5 expression comes about recognize ABCB5 as a novel atomic marker of therapy refractory tumor cells in colorectal growth patients and indicate a requirement for reliable annihilation of ABCB5-positive safe tumor cell populaces for more successful colorectal disease treatment. Additionally more than 80% of colon malignancy advancement and movement is a consequence of the deregulation of β-catenin flagging pathway. An abnormal state of the β-catenin/Tcf transcriptional complex created by the collection of β–catenin is related with human colon malignancy and colon carcinogenesis.

 Keywords: Colon cancer, ABCB5, β-catenin

Cite this Article

Tanvee Pardeshi, Nilamoni Kalita, Sameer Chaudhary et al. ABCB5 and β-catenin activity for colon cancer: A review. Research & Reviews: A Journal of Drug Design & Discovery. 2017; 4(3): 6–18p.

Full Text:



Kopetz, S.; Chang, G.J.; Overman, M.J.; Eng, C.; Sargent, D.J.; Larson, D.W.; Grothey, A.; Vauthey, J.N.; Nagorney, D.M.; McWilliams, R.R. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009, 27, 3677–3683.

Rustgi, A.K. The genetics of hereditary colon cancer. Genes Dev. 2007, 21, 2525–2538.

Yang, K.; Kurihara, N.; Fan, K.; Newmark, H.; Rigas, B.; Bancroft, L.; Corner, G.; Livote, E.; Lesser, M.; Edelmann, W.; et al. Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Res. 2008, 68, 7803–7810.

Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138, 2101–2114.e5.

Chen, L.W.; Egan, L.; Li, Z.W.; Greten, F.R.; Kagnoff, M.F.; Karin, M. The two faces of IKK and NF-kappaB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med. 2003, 9, 575–581.

Hanada, T.; Kobayashi, T.; Chinen, T.; Saeki, K.; Takaki, H.; Koga, K.; Minoda, Y.; Sanada, T.; Yoshioka, T.; Mimata, H.; et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 2006, 203, 1391–1397.

Feagins, L.A.; Souza, R.F.; Spechler, S.J. Carcinogenesis in IBD: Potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 297–305.

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004; 22:3766–75.

Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234

Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009 14: 3–9.

Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug–drug interactions. Curr Drug Deliv 2007 4: 324333.

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer 2002 2: 48–58.

Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001 11: 1156–1166.

Rees DC, Johnson E, Lewinson O (2009) ABC transporters: the power to change. Nat Rev Mol Cell Biol 10: 218–227.

. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Ann Rev Biochem 2002 71: 537–592.

Dean M. The genetics of ATP-binding cassette transporters. Meth Enzymol 2005 400: 409–429.

Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, et al. (2003) Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 278: 47156–47.

. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005 65: 4320–4333.

. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004 64: 4294–4301.

Chen KG, Szaka´cs G, Annereau JP, Rouzaud F, Liang XJ, et al. Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB5 beta) of the ATP-binding cassette transporter gene ABCB5 in melanoma cells and melanocytes. Pigment Cell Res 2005 18: 102–112.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. Identification of cells initiating human melanomas. Nature 2008 451: 345–349.

Cheung ST, Cheung PF, Cheng CK, Wong NC, Fan ST. Granulin- Epithelin Precursor and ATP-Dependent Binding Cassette ABCB5 Regulate Liver Cancer Cell Chemoresistance. Gastroenterology 2010 (in Press).

. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 2006 1(1): e98.

Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, et al. Upregulation of stem cell genes in multidrug-resistant K562 leukemia cells. Leuk Res 2009 33: 1379–1385.

Schatton T, Frank MH Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008 21: 39–55.

. Frank NY, Frank MH. ABCB5 gene amplification in human leukemia cells. Leuk Res 2009 33: 1303–1305.

Kalow W, Meyer U, Tyndale R. Pharmacogenomics. New York: Marcel Dekker, Inc.

Moon RT, Kohn AD, Ferrari GVD, Kaykas A. WNT and [beta]-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5:691–701.

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signal¬ing: components, mechanisms, and diseases. Dev Cell. 2009; 17:9–26.

Aberle H, Schwartz H, Kemler H: Cadherin–catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996, 61:514-523.

McCrea PD, Turck CW, Gumbiner B: A homolog of the Drosophila protein armadillo (Plakoglobin) associates with E-cadherin. Science 1991, 254:1359-1361.

Siegfried P, Perrimon N: Drosophila wingless: a paradigm for the function and mechanism of Wnt signaling. Bioessays 1994, 16:395-404.

Miller JR, Moon RT: Signal transduction through b-catenin and specification of cell fate during embryogenesis. Genes Dev 1996, 10:2527-2539.

Han M: Gut reaction to Wnt signaling in worms. Cell 1997, 90:581-584.

Nusse R, Varmus HE: Wnt genes. Cell 1992, 69:1073-1087.

Schneikert J, Behrens J. The canonical Wnt signalling path¬way and its APC partner in colon cancer development. Gut. 2007; 56:417–425.

Kobayashi M, Honma T, Matsuda Y, Suzuki Y, Narisawa R, et al. (2000) Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer 82: 1689–1693

Saif MW, Chu E. Biology of colorectal cancer. Cancer J 2010 16: 196–201.

Bienz M, Clevers H. Linking colorectal cancer to wnt signaling. Cell 2000 103: 311–320

Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012 487: 330–337.

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011 17: 1452–1462.

Herencia C, Julio M, Moreno M, et al. Nuclear translocation of b-Catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS ONE. 2012; 7: e34656.

Heiser PW, Cano DA, Landsman L, et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology. 2008; 135: 1288–300.

Stauffer JK, Scarzello AJ, Andersen JB, et al. Coactivation of AKT and b-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res. 2011; 71: 2718– 27.

Pacheco-Pinedo EC, Durham AC, Stewart KM, et al. Wnt/b-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011; 121: 1935–45.

Rogers HA, Sousa S, Salto C, et al. WNT/ b-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer. 2012; 107: 1144–52.

Gat U, DasGupta R, Degenstein L, et al. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell. 1998; 95: 605–14.

Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999; 18: 5931–42.

Sparks AB, Morin PJ, Vogelstein B, et al. Mutational analysis of the APC/beta-catenin/ Tcf pathway in colorectal cancer. Cancer Res. 1998; 58: 1130–4.


  • There are currently no refbacks.

Copyright (c) 2018 Research & Reviews: A Journal of Drug Design & Discovery